Data investigation

Cheapest GLP-1 Without Insurance in 2026: Buyer's Guide

The lowest legitimate GLP-1 price in 2026 is $149/month, for Foundayo (oral orforglipron) or the Wegovy pill, though top doses cost more. Injectables run $349/month for the Wegovy pen and $299 to $449/month for LillyDirect Zepbound vials. Compounded options remain unsettled.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
13 min read·14 citations

Cash-pay GLP-1 pricing changed dramatically in late 2025 and early 2026. NovoCare Pharmacy repriced Wegovy from $499 to $349/month for the standard pen ($199 for a new patient's first two months) and launched a $149/month oral pill. LillyDirect Self Pay Pharmacy launched Zepbound vials at $299-$449/month by dose tier. Eli Lilly launched Foundayo (orforglipron) starting at $149/month for the lowest dose, the first oral small-molecule GLP-1, via LillyDirect and Amazon Pharmacy. This article walks every legitimate cash-pay tier in cost-ascending order, with verified pricing, regulatory caveats, and magnitude-vs-cost comparisons. Research-peptide and OTC “natural Ozempic” supplement options are deliberately excluded as not legitimate.

The honest answer

The lowest legitimate GLP-1 starting price in 2026 is $149/month: Foundayo (oral orforglipron) via LillyDirect or Amazon Pharmacy, and the Wegovy oral pill (1.5 mg) via NovoCare. That is the first-step price. At 17.2 mg, Foundayo is $299-$349/month, and the 25 mg Wegovy pill is $299/month. Compounded semaglutide can be cheaper ($99-$300/month) but the regulatory grace period ended in early 2025 — legal status is unsettled. Manufacturer patient assistance programs do not cover the weight-loss brands: Lilly Cares does not list Zepbound, Mounjaro or Foundayo, and the Novo Nordisk PAP gives free Ozempic, not Wegovy, to uninsured households at or below 200% of the Federal Poverty Level.

Real retail cost of GLP-1s in 2026 (the $1,300/month problem)

The list price of FDA-approved GLP-1 medications is approximately $1,000-$1,350 per month at retail without insurance, depending on the product, the dose, and the dispensing pharmacy. That is the price your local CVS, Walgreens, or Walmart will quote you at the counter for a 4-week supply of brand-name Wegovy, Zepbound, Ozempic, or Mounjaro if you walk in with a prescription and pay cash — no insurance, no manufacturer program, no coupon.

That headline number is what drove the compounded-GLP-1 telehealth industry that dominated 2023 and 2024, and what continues to drive the gray-market “research peptide” market into 2026. The good news is that the legitimate cash-pay landscape has changed materially since late 2025. The manufacturers themselves launched direct-to-patient channels at much lower prices to defend market share against compounded competitors. Costco launched member-only pricing for Wegovy and Ozempic. Amazon Pharmacy entered as a third Foundayo channel. The result is that the $1,300/month wall has cracks — large ones.

The legitimate cash-pay GLP-1 landscape in 2026, sorted cheapest to most expensive: The federal listing that gathers the brand-name cash prices in one place is covered dose by dose in what TrumpRx charges for each GLP-1, including why those numbers match LillyDirect and NovoCare exactly.

TierProductChannelMonthly cost
1Novo Nordisk PAP: Ozempic only (uninsured, income at or below 200% FPL)Direct manufacturer assistance$0
2Compounded semaglutide (regulatory caveat)503A telehealth pharmacies$99-$300
3Foundayo (orforglipron oral)LillyDirect / Amazon Pharmacy$149-$349
4Wegovy oral pill (semaglutide 1.5-25 mg oral)NovoCare Pharmacy$149-$299
5Wegovy standard pen (0.25-2.4 mg)NovoCare Pharmacy$199-$349
6Zepbound vials (2.5-15 mg dose tiers)LillyDirect Self Pay Pharmacy$299-$449
7Wegovy or OzempicCostco Member Value Pricing (Costco Pharmacy)$199 (2 starter fills), then $349
8Brand Wegovy / Zepbound / Ozempic / MounjaroRetail pharmacy, no insurance$1,000-$1,350

The rest of this article walks each tier in detail with the regulatory, clinical, and practical caveats. The single most important point: the lowest starting price for a legitimate FDA-approved GLP-1 in 2026 is $149/month, not $1,300/month, and the top doses run about $299 to $449/month. If you are still seeing $1,000+ quoted in old articles or at a retail pharmacy counter, the manufacturer’s direct-to-patient channel is the lever — not insurance, not a coupon, not a research peptide.

If you choose compounded semaglutide — top vetted providers by editorial score

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Starting price: $169/mo (12-month plan rate)

Get started →Read review Found →

Lowest starting price: Foundayo oral from $149/month

Foundayo is the brand name for orforglipron, the first FDA-approved oral small-molecule GLP-1 receptor agonist. It is a non-peptide GLP-1 agonist that survives the gastric environment without needing the absorption- enhancer formulation that the oral semaglutide products require, which means once-daily oral dosing without the fasting-window protocol that Rybelsus and Wegovy oral pill demand. Eli Lilly launched Foundayo commercially after its April 1, 2026 FDA approval with a deliberately aggressive direct-to- patient cash-pay price. [4]

The launch pricing per the Eli Lilly Investor Relations release of December 1, 2025:

  • From $149 per month at LillyDirect Self Pay Pharmacy (lillydirect.lilly.com), Lilly’s direct-to-patient channel that ships the product nationally with cold-chain-not-required ground shipping.
  • From $149 per month at Amazon Pharmacy (pharmacy.amazon.com), which operates as a U.S.-licensed mail-order pharmacy filling FDA-approved Foundayo prescriptions at parity with the LillyDirect price. Prime membership is not required. [10]

The clinical magnitude per ATTAIN-1, the pivotal Phase 3 trial that supported the FDA approval: oral orforglipron at the top dose (36 mg in the trial, sold as the 17.2 mg tablet) produced approximately -11.2% body weight at week 72 in adults with obesity, versus -2.1% on placebo. [3] That sits below the FDA-approved injectables (Wegovy ~15%, Zepbound ~21% TBWL) and below the 25 mg Wegovy pill, which reached -13.6% vs -2.4% on placebo at week 64 in the label’s Study 7, a separate trial. [14] The $149 price is for the starting dose only: at 17.2 mg, Foundayo costs $299-$349/month, about the same as the $349 Wegovy pen.

Why Foundayo is the headline starting tier

  • FDA-approved, full pharmaceutical quality, brand-name product.
  • Two parallel channels (LillyDirect, Amazon Pharmacy) at the same price.
  • Oral once-daily; no injection, no cold chain.
  • $149 is the first-step price; 17.2 mg costs $299-$349/month.
  • Clinical magnitude is ~11% TBWL at the top dose, below the -13.6% for the 25 mg Wegovy pill in a separate trial.
  • No FDA Drug Shortage exposure (orforglipron has never been in shortage).

See our companion piece on where to buy Foundayo for the full channel-by-channel breakdown including ship times, prescription transfer, and the LillyDirect vs Amazon Pharmacy prescriber-credential differences.

Wegovy oral pill at NovoCare (from $149/month)

Novo Nordisk responded to the Foundayo launch with a parallel oral product starting at $149/month: the Wegovy oral pill, a once-daily semaglutide tablet (1.5 mg up to 25 mg) dispensed through NovoCare Pharmacy, Novo Nordisk’s direct-to-patient channel. [5] This is the same active ingredient as injectable Wegovy and Ozempic (semaglutide), reformulated for oral administration with the absorption-enhancer SNAC that is also used in Rybelsus — the oral semaglutide product Novo Nordisk has marketed for type 2 diabetes since 2019. Some telehealth memberships, such as Healthspan, prescribe the Wegovy pill and send it to NovoCare Pharmacy, with the membership billed separately from the medication.

The clinical magnitude data on the Wegovy oral pill at 25 mg is closer to injectable semaglutide than Rybelsus 14 mg was: in the label’s Study 7, the 25 mg tablet reached -13.6% vs -2.4% on placebo at week 64. [14] Study 7 was placebo-controlled, so the comparison with the 2.4 mg injection is across trials, not head-to-head. The oral product avoids the injection and injection-site reactions. The protocol is once-daily oral on an empty stomach with no food or other oral medication for 30 minutes afterward — the standard SNAC absorption-window protocol.

Practical considerations for the Wegovy oral pill at NovoCare:

  • Price: $149/month for 1.5 mg, $199/month for 4 mg, and $299/month for 9 mg and 25 mg.
  • Channel: NovoCare Pharmacy direct-to-patient (novocare.com). Single-pipeline dispensing — not available at Costco or Amazon Pharmacy at this price tier as of 2026.
  • Prescription: Required. NovoCare partners with telehealth clinicians who can issue the prescription if you do not have a treating prescriber.
  • Protocol: Once-daily oral on empty stomach; 30 minutes before food, beverages other than water, and other oral medications.
  • Storage: Room temperature; no refrigeration; no cold-chain shipping.
  • Eligibility: Verified cash-pay (uninsured or insurance-declined). Insurance with Wegovy coverage routes through the standard pharmacy channel at the negotiated insurance price.

Compounded semaglutide: $99-$300/month with regulatory caveats

Compounded semaglutide can be cheaper than Foundayo or the Wegovy oral pill — the floor sits at $99/month for the cheapest providers, with the median in the $150-$250/month range. This is real pharmaceutical-grade semaglutide compounded by 503A state-licensed pharmacies from FDA-registered API supply, dispensed against a prescription from a telehealth clinician. Our companion piece verifies every provider at the floor price against licensing, pharmacy partner, and dose. Many compounded programs price by dose, so the entry price can climb as you titrate; our flat-price GLP-1 providers charge the same at every dose, and our list of GLP-1 providers with no membership fee covers the ones that put no membership on top of the medication. Panterra Health, a newer service, does both: one price at every dose, with the medication, visit and shipping in each refill and no membership. Collective’s membership model works the other way: a flat medication price at every dose, with a required annual membership billed on top, so add that yearly fee before you compare.

The regulatory landscape is where the asterisk lives. The FDA Drug Shortage list declared injectable semaglutide resolved on February 21, 2025. Per FDA enforcement-discretion policy, the deadlines that followed were:

  • April 22, 2025: 503A state-licensed pharmacy enforcement-discretion ended for compounded semaglutide. [7]
  • May 22, 2025: 503B outsourcing-facility enforcement- discretion ended for compounded semaglutide. [7]

After those dates, broad commercial compounded semaglutide sits outside the FDA enforcement-discretion framework. Many telehealth providers continue dispensing under narrow patient-specific 503A clinical- necessity authority (e.g., documented allergy to a Wegovy inactive ingredient, documented dose strength not available in the approved product). The legal status varies by state board of pharmacy interpretation. The product itself is pharmaceutical-grade and dispensed through a licensed pharmacy — but the “is this commercial compounding still permitted” question is unsettled. [8]

Compounded semaglutide buyer checklist

  • LegitScript Healthcare Merchant Certification on the telehealth provider.
  • NABP “.pharmacy” domain, VIPPS accreditation, or NABP non-recommendation lookup on the dispensing pharmacy.
  • FDA-registered API supplier for the bulk semaglutide.
  • USP <797> sterile-compounding standards documented.
  • Patient-prescriber relationship with a licensed clinician — not just a checkbox intake.
  • Refund policy and adverse-event reporting pathway disclosed in writing.

The honest framing: with legitimate brand Foundayo or the Wegovy oral pill starting at $149/month, the cost gap that drove the compounded semaglutide market in 2023-2024 has narrowed. But $149 is the starter price. The compounded floor ($99/month) is $50 below it, while the brand pills run $299-$349/month at the doses behind the trial results, so the real gap depends on your dose. Whether the regulatory certainty of the brand channels is worth that difference is a personal call. If you compare compounded prices, check who actually sets them, since telehealth brands merge: MyDietDoc, for example, now forwards patients to BiltRx, a separate company with its own prices and terms.

Costco Member Value Pricing (Costco Pharmacy)

Costco Member Value Pricing is Costco’s own members-only savings program, administered by Costco Pharmacy and Ventegra; it is not insurance. Costco Pharmacy fills FDA-approved brand Wegovy and Ozempic for warehouse pick-up or home delivery at $199 a month for the 0.25/0.5 mg starter doses (limited to two fills), then $349 a month for Wegovy 1–2.4 mg or Ozempic 1 mg. [9] Sesame is a separate, optional step: Costco members get Sesame member pricing, a $29 virtual primary care visit and 10% off other Sesame services, and a Sesame clinician’s prescription can be filled at Costco or any other pharmacy.

Costco Member Value Pricing at a glance:

  • Eligibility: Costco members only; claims billed to Medicare, Medicaid or private insurance aren’t eligible.
  • Prescription: any licensed prescriber; Costco members pay $29 for a Sesame virtual primary care visit if they need one (separate from the drug cost).
  • Drug cost: Wegovy $349 per month at 1–2.4 mg and Ozempic $349 at 1 mg ($499 at 2 mg); Wegovy HD 7.2 mg $399; Wegovy tablets $149–$299 by dose. The $199 starter tier rises to $349 after 12/31/26.
  • Product: FDA-approved brand Wegovy / Ozempic from Novo Nordisk; full pharmaceutical quality.
  • Fulfillment: Costco Pharmacy, by warehouse pick-up or home delivery.

Where Costco Member Value Pricing sits in the cost stack: its Wegovy and Ozempic prices match Novo Nordisk’s own self-pay prices, which Novo offers through 70,000+ pharmacies, so they are not a Costco-exclusive discount. The standard Wegovy pen is the same $349 as at NovoCare Pharmacy and more expensive than the $149 oral tiers (Foundayo, Wegovy oral pill). It is most useful when you already have a Costco membership and want to pick up brand Wegovy or Ozempic injectable at a warehouse pharmacy.

Wegovy NovoCare pen + LillyDirect Zepbound vials ($299-$449)

The injectable cash-pay tiers from the manufacturers’ direct channels:

Wegovy standard pen at NovoCare: $349/month

NovoCare Pharmacy dispenses the standard Wegovy autoinjector pen (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg dose ladder) at $349 per month regardless of dose, after $199/month for a new patient's first two fills of 0.25 mg and 0.5 mg. This is the same physical product as the retail Wegovy pen — full pharmaceutical quality, cold-chain ground shipping, four single-use pens per month. The price was repriced down from $499/month in late 2025 amid a broader cash-pay market shift. [5]

LillyDirect Self Pay Zepbound vials: $299/$399/$449

LillyDirect Self Pay Pharmacy dispenses Zepbound in single-dose vial format at the dose-tier pricing established in the Eli Lilly Investor Relations release of December 1, 2025: [4]

  • $299/month for the 2.5 mg single-dose vial (titration start dose).
  • $399/month for the 5 mg single-dose vial.
  • $449/month for the 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose vials.

The vial format requires a syringe draw rather than the prefilled autoinjector pen, but the product is genuine brand Zepbound from the FDA-approved Eli Lilly manufacturing chain, with all USP quality testing intact. A prescription is required; LillyDirect routes through partnered telehealth clinicians if you do not have a treating prescriber.

Patient Assistance Programs + copay savings cards

Manufacturer patient assistance programs are narrower than many cost guides suggest. Lilly Cares does not list Zepbound, Mounjaro or Foundayo; its only GLP-1 is Trulicity, a type 2 diabetes medicine, for households at or below 300% of the Federal Poverty Level who have no insurance or have Medicare Part D. [11] The Novo Nordisk Patient Assistance Program lists Ozempic but not Wegovy, and Ozempic is offered through it to uninsured patients only. [12]

Who qualifies for free Ozempic through the Novo Nordisk PAP

The 2026 rules for Ozempic through the Novo Nordisk PAP:

  • Income: Household income at or below 200% of the Federal Poverty Level. For 2026, that is about $31,920 for one person and $66,000 for a family of four in the 48 contiguous states. [12] [13]
  • Insurance: No insurance. People with private or commercial insurance are not eligible, Medicare Part D enrollees cannot get Ozempic through the program, and applicants cannot be enrolled in or qualify for Medicaid, Extra Help or VA benefits.
  • Documentation: An application completed by you and your prescriber, plus a copy of a state Medicaid denial letter; proof of income is needed if you did not file taxes.
  • Cost: No registration charge or monthly fee.

If your household has no insurance, is under that income limit, and your doctor has prescribed Ozempic, $0/month is the cheapest legitimate brand-name GLP-1. For weight loss with Wegovy, Zepbound or Foundayo, no manufacturer program gives the drug away; the lowest legitimate starting price is the $149/month Foundayo or Wegovy pill tier covered above.

Manufacturer copay savings cards

For commercial-insurance patients with GLP-1 coverage subject to a high copay or coinsurance, manufacturer copay savings cards can bring out-of-pocket cost to as low as $25 per month:

  • Wegovy Savings Card (Novo Nordisk) — reduces eligible commercial-insurance out-of-pocket cost for Wegovy. Eligibility excludes Medicare, Medicaid, and other federal-program beneficiaries.
  • Zepbound Savings Card (Eli Lilly) — same structure for Zepbound; excludes federal-program beneficiaries.
  • Ozempic Savings Card (Novo Nordisk) — for type 2 diabetes patients with commercial coverage. Our walkthrough of the $25-a-month Ozempic card covers who qualifies, how to enroll and where the savings cap kicks in.
  • Mounjaro Savings Card (Eli Lilly) — for type 2 diabetes patients with commercial coverage.

See our GLP-1 cash-pay coupon channel guide for the full breakdown including GoodRx, Sam’s Club Plus Pharmacy, and the channel-by-channel comparison for any combination of insurance status and drug.

What we don’t recommend (research peptides, OTC supplements)

Two categories of products advertise GLP-1-class weight-loss outcomes at prices far below the legitimate tiers above. Neither belongs in this buyer’s guide.

Chemistry-supply websites sell lyophilized semaglutide and tirzepatide vials at $80-$300 per vial, labeled “for research use only, not for human consumption.” These products have no FDA quality testing — no USP identity, no purity, no sterility, no endotoxin testing, no dose-accuracy verification. The “research use only” disclaimer is the seller’s legal shield against the distribution charge; it does not legalize personal-use injection by the buyer. Customs routinely seizes inbound shipments. Documented dosing errors up to 20-fold the intended dose have been reported with similar non-brand lyophilized GLP-1 products.

With FDA-approved Foundayo or the Wegovy oral pill starting at $149/month and running $299-$349/month at top doses, the cost gap that drove the research-peptide market has narrowed. See our full research-peptide debunker for the regulatory, quality, and enforcement detail.

Berberine, apple cider vinegar gummies, GLP-1 patches, sublingual GLP-1 sprays, and the various “natural Ozempic” supplements marketed at $30-$80 per month produce zero to negligible weight loss in controlled studies. The published berberine meta-analysis shows roughly 2-4 lbs of weight reduction over 12 weeks — versus the 35-50 lbs documented in STEP-1 and SURMOUNT-1 for FDA-approved semaglutide and tirzepatide. [1] [2] There is no transdermal, sublingual, or oral-spray formulation of any GLP-1 receptor agonist with FDA approval or with documented bioequivalence to the FDA-approved subcutaneous or oral products. Foundayo and the Wegovy oral pill start at $149/month and are real GLP-1s; the $30/month supplement is not a GLP-1 at all.

Cost-per-pound-lost: magnitude vs cost

The headline price is only half the picture. The other half is the clinical magnitude — how much weight loss the product produces at its labeled maximum dose. Combining the two gives a cost-per- percentage-point of total body weight lost (TBWL), which is the most useful single metric for comparing options.

Magnitude comparison

Weight-loss magnitude — FDA-approved GLP-1s at labeled maximum dose[1][2][3]

  • Berberine (supplement, 12 wk)2 % TBWL
    approximate; not a GLP-1
  • Foundayo (36 mg in the trial, sold as 17.2 mg; ATTAIN-1)11 % TBWL
  • Wegovy (semaglutide 2.4 mg SC, STEP-1)15 % TBWL
  • Zepbound (tirzepatide 15 mg SC, SURMOUNT-1)21 % TBWL
Weight-loss magnitude — FDA-approved GLP-1s at labeled maximum dose

Combining magnitude with the 12-month cash-pay cost for a 180-lb starting weight (where TBWL converts to absolute pounds):

Product (max dose)TBWLPounds lost (180 lb start)12-mo cost$ per lb lost
Foundayo oral 17.2 mg ($299-$349/mo)~11%~20 lb$3,588-$4,188~$179-$209/lb
Wegovy oral pill 25 mg ($299/mo)~13.6%~24 lb$3,588~$150/lb
Wegovy pen 2.4 mg ($349/mo)~15%~27 lb$4,188~$155/lb
Zepbound vial 15 mg ($449/mo)~21%~38 lb$5,388~$143/lb

Foundayo's $149/month price applies to the starting dose, not to the dose behind the ~11% result. At 17.2 mg the self-pay price is $349/month, or $299 with a refill within 45 days of the previous fill, which works out to about $179 to $209 per pound. At maintenance doses the Wegovy pill ($299 at 25 mg) and the Wegovy pen ($349) land between $150 and $155 per pound, and Zepbound produces the largest absolute weight loss at the highest monthly price but a lower cost per pound than the Wegovy pen. There is no $0 row because no manufacturer assistance program covers these weight-loss products. Run your own numbers with our GLP-1 cost-per-pound calculator and the GLP-1 savings calculator for your specific starting weight, target weight, and insurance situation.

Bottom line

  • The lowest starting price for a legitimate FDA-approved GLP-1 in 2026 is $149/month — Foundayo (oral orforglipron) via LillyDirect or Amazon Pharmacy, or Wegovy oral pill (1.5 mg) via NovoCare Pharmacy.
  • Compounded semaglutide can be cheaper ($99-$300/month) but the FDA enforcement-discretion grace period ended in April-May 2025; the legal status of broad commercial compounding is unsettled.
  • The Wegovy standard pen at NovoCare is $349/month after $199 for a new patient's first two months (repriced from $499 in late 2025); LillyDirect Self Pay Zepbound vials are $299/$399/$449/month by dose tier per the Lilly IR Dec 1, 2025 release.
  • Costco Member Value Pricing (Costco Pharmacy, members only) charges $349/month for brand Wegovy 1–2.4 mg or Ozempic 1 mg after two $199 starter fills; a Sesame visit for the prescription is optional ($29 for Costco members).
  • No manufacturer assistance program gives away Wegovy, Zepbound, Mounjaro or Foundayo. The Novo Nordisk PAP covers Ozempic only, free for uninsured households at or below 200% of the Federal Poverty Level; Lilly Cares’ only GLP-1 is Trulicity, at or below 300%.
  • Research-chemical peptides and OTC “natural Ozempic” supplements are not in the comparison. The first is illegal and has no FDA quality testing; the second has no weight-loss effect comparable to a real GLP-1.
  • See our GLP-1 pricing index for the live-tracking dataset that underpins this article.

Our reviews

Providers that prescribe GLP-1s online

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Foundayo (orforglipron), the new oral small-molecule GLP-1 receptor agonist from Eli Lilly, launched commercially starting at $149 per month for the lowest dose via LillyDirect Self Pay Pharmacy and Amazon Pharmacy. Wegovy oral pill (once-daily semaglutide tablet) launched in parallel at $149 per month for the 1.5 mg starting dose via NovoCare Pharmacy. Both are FDA-approved brand-name products with full pharmaceutical quality. Compounded semaglutide can be cheaper ($99-$300 per month at the floor) but operates outside the FDA enforcement-discretion framework that ended in early 2025 — the legal landscape is unsettled. Manufacturer patient assistance programs do not cover Wegovy, Zepbound or Foundayo; the Novo Nordisk PAP gives free Ozempic only, to uninsured households at or below 200% of the Federal Poverty Level.
Several telehealth providers continue to advertise compounded semaglutide at $99 per month through 503A state-licensed pharmacies. The product itself, when sourced from a LegitScript-certified pharmacy with FDA-registered API supply, is pharmaceutical-grade semaglutide. The regulatory question is harder: the FDA Drug Shortage list declared semaglutide injectable resolved on February 21, 2025; 503A enforcement-discretion ended April 22, 2025, and 503B ended May 22, 2025. Broad commercial compounded semaglutide now sits outside the 503A enforcement-discretion framework. Many providers continue under narrow patient-specific 503A clinical-necessity authority. The legal status varies by state and is unsettled. Our companion piece /research/cheapest-compounded-semaglutide tracks every provider at the floor price with pharmacy-licensing verification.
Wegovy without insurance has two cash-pay tiers as of 2026. The Wegovy oral pill (once-daily semaglutide tablet) is $149 per month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg via NovoCare Pharmacy, Novo Nordisk's direct-to-patient channel. The Wegovy standard subcutaneous pen (0.25 mg to 2.4 mg dose ladder) was repriced from $499 to $349 per month via NovoCare Pharmacy in late 2025, with $199 for a new patient's first two months. Both are dispensed from a single direct-to-patient pipeline; the oral pill avoids the injection. Costco Pharmacy charges Costco members the same $349 per month under Costco Member Value Pricing.
Zepbound cash-pay vials at LillyDirect Self Pay Pharmacy are priced by dose tier: $299 per month for the 2.5 mg single-dose vial, $399 per month for the 5 mg single-dose vial, and $449 per month for the 7.5 mg and higher dose vials, per the Eli Lilly Investor Relations release of December 1, 2025. The vial format requires a syringe draw rather than the prefilled autoinjector pen, but the product is genuine brand Zepbound from the FDA-approved manufacturing chain with all USP quality testing intact. Insurance with prior authorization can bring out-of-pocket cost dramatically lower; commercial insurance + Zepbound Savings Card can hit as low as $25 per month for eligible patients.
Yes, for chronic weight management indications. Zepbound, Wegovy, and Foundayo when prescribed for chronic weight management are HSA-eligible and FSA-eligible medical expenses under IRS Publication 502 because they treat a specific medical condition (obesity, defined by BMI threshold and comorbidity). Ozempic and Mounjaro when prescribed for type 2 diabetes are also HSA- and FSA-eligible. The IRS does not allow HSA or FSA reimbursement for GLP-1 prescribed solely for cosmetic weight loss without a medical-necessity diagnosis. Save the pharmacy receipt and the prescription documentation; HSA administrators may request the prescription on audit.
Neither program covers the weight-loss brands. Lilly Cares does not list Zepbound, Mounjaro or Foundayo; its only GLP-1 is Trulicity, a type 2 diabetes medicine, for households at or below 300% of the Federal Poverty Level ($47,880 for one person, $99,000 for a family of four in 2026) who have no insurance or have Medicare Part D. The Novo Nordisk Patient Assistance Program lists Ozempic but not Wegovy. Ozempic through the program is free for uninsured patients with household income at or below 200% of the Federal Poverty Level (about $31,920 for one person, $66,000 for a family of four); people with private or commercial insurance and Medicare Part D enrollees cannot get Ozempic through it. There is no registration charge or monthly fee.
Because it is illegal, the product has no FDA quality testing, and the downside is severe. Research-chemical tirzepatide and semaglutide are sold by chemistry-supply vendors under 'for research use only, not for human consumption' disclaimers. That disclaimer is the seller's legal shield against the distribution charge — it does not legalize personal-use injection by the buyer. The product has no USP identity testing, no sterility testing, no endotoxin testing, no dose-accuracy verification, and no adverse-event recourse. Customs routinely seizes inbound shipments. Payment processors unwind merchant accounts without refund. Documented dosing errors up to 20-fold the intended dose have been reported with similar non-brand lyophilized GLP-1 products. The legitimate tiers above, starting at $149 and running $299-$449 at top doses, have narrowed the cost gap that drove the research-peptide market in 2023-2024. See /research/buy-tirzepatide-peptide-research-chemical-debunker.
The $25-per-month figure comes from manufacturer copay savings cards — the Wegovy Savings Card and Ozempic Savings Card from Novo Nordisk — not from a cash-pay program. Those cards require commercial insurance that already covers the drug, and they explicitly exclude uninsured patients as well as Medicare, Medicaid, and other federal-program beneficiaries. So '$25 a month without insurance' is largely a myth for the uninsured: if you have no coverage, the lowest legitimate semaglutide starting price is the Wegovy oral pill at $149 per month via NovoCare, or compounded semaglutide from about $99 per month subject to the regulatory caveats above. The $25 tier only becomes real once commercial insurance is in the picture.
Under Costco Member Value Pricing, Costco Pharmacy charges members $349 per month for brand Wegovy (1-2.4 mg) or Ozempic (1 mg), with $199 for the first two fills of the 0.25/0.5 mg starter doses. It requires an active Costco membership, is not insurance, and dispenses FDA-approved brand-name product. Sesame is optional: Costco members can get a $29 Sesame virtual visit for the prescription, which can be filled at Costco or anywhere else. The $349 tier is more expensive than the $149-per-month oral tiers (Foundayo, Wegovy oral pill) and the same as the Wegovy pen at NovoCare Pharmacy, so Costco is most useful when you already have a membership and want to pick up brand injectable Wegovy or Ozempic at the warehouse.
None of them work. Berberine, apple cider vinegar gummies, GLP-1 patches, sublingual GLP-1 sprays, and the various 'natural Ozempic' supplements marketed at $30-$80 per month produce zero to negligible weight loss in controlled studies. The published berberine meta-analysis shows roughly 2-4 lbs of weight reduction over 12 weeks, versus the 35-50 lbs of weight reduction documented in STEP-1 and SURMOUNT-1 for FDA-approved semaglutide and tirzepatide. There is no transdermal, sublingual, or oral-spray formulation of semaglutide, liraglutide, or tirzepatide with FDA approval or with bioequivalence to the subcutaneous injectable. Foundayo and the Wegovy oral pill start at $149/month and are real GLP-1s; the $30/month supplement is not a GLP-1 at all.

Further reading

Pricing verification. Foundayo $149/month and LillyDirect Self Pay Zepbound $299/$399/$449/month per the Eli Lilly Investor Relations release of December 1, 2025. NovoCare Pharmacy Wegovy oral pill $149/$199/$299 per month (1.5/4/9-25 mg) and Wegovy standard pen $349/month ($199 for the first two months) per Novo Nordisk's savings-offer page. Costco Member Value Pricing Wegovy $199 (two starter fills) / $349 per month per Costco Pharmacy’s price tool. Compounded semaglutide floor $99/month per the live verification in /research/cheapest-compounded-semaglutide. All FDA regulatory dates verified against the FDA Drug Shortage list and the FDA Declaratory Order of December 19, 2024.

Weight Loss Rankings does not prescribe, dispense, or endorse any specific compounding pharmacy or gray-market product. Pricing is current as of the publication date and changes — see the linked GLP-1 pricing index for the live dataset.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP-1. Semaglutide 2.4 mg subcutaneous once-weekly produced -14.9% mean body-weight reduction versus -2.4% placebo at week 68 in 1,961 adults with overweight or obesity. This is the canonical magnitude benchmark cited throughout the article for what FDA-approved injectable semaglutide produces at the labeled maximum dose. N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. Subcutaneous tirzepatide 5 mg, 10 mg, and 15 mg once-weekly produced mean body-weight reductions of -15.0%, -19.5%, and -20.9% respectively versus -3.1% placebo at week 72 in 2,539 adults with obesity. This is the canonical magnitude benchmark for FDA-approved injectable tirzepatide cited throughout the article. N Engl J Med. 2022. PMID: 35658024.
  3. 3.Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. ATTAIN-1. Once-daily oral orforglipron at the top dose (36 mg in the trial, sold as the 17.2 mg tablet) produced approximately -11.2% body weight, versus -2.1% on placebo, at week 72 in adults with obesity. This is the canonical magnitude benchmark for the new oral GLP-1 class cited throughout the article; orforglipron is the active ingredient in Foundayo. N Engl J Med. 2025. PMID: 40960239.
  4. 4.Eli Lilly and Company, Investor Relations. Lilly announces LillyDirect Self Pay Pharmacy Zepbound vial pricing: $299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg and higher dose vials. Launch of Foundayo (orforglipron) at $149 per month via LillyDirect Self Pay Pharmacy and Amazon Pharmacy. Press release December 1, 2025. Eli Lilly and Company Investor Relations. 2025. https://investor.lilly.com/news-releases
  5. 5.Novo Nordisk Inc. NovoCare Pharmacy direct-to-patient cash-pay program. Wegovy standard pen (0.25 mg to 2.4 mg dose ladder) repriced from $499 to $349 per month in late 2025 ($199 for a new patient's first two months). Wegovy oral pill launched in parallel at $149 per month for the 1.5 mg dose ($199 at 4 mg, $299 at 9 mg and 25 mg). Single direct-to-patient pipeline; verification of cash-pay eligibility at enrollment. NovoCare Pharmacy. 2026. https://www.novocare.com
  6. 6.U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide. December 19, 2024. FDA reconfirmed the tirzepatide shortage was resolved. Enforcement-discretion deadlines set for state-licensed 503A pharmacies (February 18, 2025) and 503B outsourcing facilities (March 19, 2025) for compounded tirzepatide. U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/184606/download
  7. 7.U.S. Food and Drug Administration. FDA Drug Shortages: Semaglutide Injection — Resolved. Semaglutide injectable shortage declared resolved February 21, 2025. 503A state-licensed pharmacy enforcement-discretion for compounded semaglutide ended April 22, 2025; 503B outsourcing-facility enforcement-discretion ended May 22, 2025. After these dates, broad commercial compounded semaglutide sits outside the enforcement-discretion framework; only narrow patient-specific 503A clinical-necessity compounding remains. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection
  8. 8.U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Agency statement explaining the post-shortage compounding policy framework for tirzepatide and semaglutide, including the section 503A and 503B enforcement-discretion timelines. U.S. Food and Drug Administration. 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  9. 9.Costco Wholesale Corporation. Costco Member Value Pricing: members-only pricing administered by Costco Pharmacy and Ventegra (not insurance). Wegovy $199 for the 0.25/0.5 mg starter doses (two fills), then $349 for 1-2.4 mg; Ozempic $199 / $349 (1 mg) / $499 (2 mg); Wegovy HD 7.2 mg $399. Costco Pharmacy. 2026. https://rx.costco.com/member-value-pricing
  10. 10.Amazon Pharmacy. Amazon Pharmacy Foundayo (orforglipron) cash-pay availability at $149 per month. Amazon Pharmacy operates as a U.S. licensed mail-order pharmacy filling FDA-approved Foundayo prescriptions at parity with the LillyDirect Self Pay launch price. Prescription required; Prime membership not required for the cash-pay price. Amazon Pharmacy. 2026. https://pharmacy.amazon.com
  11. 11.Lilly Cares Foundation, Inc. Lilly Cares: How to Apply and Available Medications. Trulicity is the only GLP-1 on the Lilly Cares medication list (Group 1: no insurance or Medicare Part D, household income at or below 300% of the 2026 Federal Poverty Guidelines, $47,880 for one person and $99,000 for four). Zepbound, Mounjaro and Foundayo are not listed. Lilly Cares Foundation. 2026. https://www.lillycares.com/how-to-apply
  12. 12.Novo Nordisk Inc. Novo Nordisk Patient Assistance Program (PAP), 2026. The PAP product list includes Ozempic (for uninsured patients only) and does not include Wegovy. Household income must be at or below 200% of the federal poverty level for Ozempic; private or commercial insurance makes a patient ineligible, and Medicare Part D beneficiaries are not eligible for the Ozempic PAP. No registration charge or monthly fee. Novo Nordisk Patient Assistance Program. 2026. https://www.novocare.com/diabetes/help-with-costs/pap.html
  13. 13.U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. 2026 Poverty Guidelines (Federal Poverty Level reference tables). The 100% FPL baseline in the 48 contiguous states is $15,960 for a single-person household and $33,000 for a family of four; 200% FPL is $31,920 and $66,000, and 300% FPL is $47,880 and $99,000. Higher thresholds apply in Alaska and Hawaii. U.S. Department of Health and Human Services ASPE. 2026. https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines
  14. 14.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets: US Prescribing Information. Section 14, Study 7 (WEGOVY 25 mg tablet vs placebo, week 64). FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Is Ozempic Available Over the Counter? Honest 2026 Evidence Review

No. Ozempic is a prescription-only drug regulated under 21 CFR Part 503. It cannot be purchased OTC at any US retailer. This article walks the four legitimate Rx pathways, the OTC supplement scam landscape, and FDA / FTC enforcement against fake 'natural Ozempic' products.

11 min read

How to Find a GLP-1 Prescriber Near You: The 2026 Patient Guide

There are four legitimate ways to access a GLP-1 in 2026: primary care or obesity-medicine in person, an accredited telehealth platform, NovoCare Pharmacy direct (Wegovy), or LillyDirect Self Pay (Zepbound and Foundayo). Any 'no-prescription' source is illegal.

13 min read

How to Get a GLP-1 Prescription in 2026: The Patient Buyer Funnel

You can get semaglutide or tirzepatide through insurance (with prior authorization), brand direct-pay (Wegovy $199-$399, Zepbound $299-$449), compounded telehealth ($150-$400/month) or the $25 oral Foundayo path. Plus red flags.

12 min read

Where to Buy Semaglutide in 2026: Verified US Provider List

There are four legitimate US channels for semaglutide in 2026: brand Wegovy or Ozempic at pharmacies with insurance, NovoCare Pharmacy direct pay, 503A compounded semaglutide through telehealth, and the insurance prior authorization path. Pricing for each and what to check.

9 min read

Where to Buy Tirzepatide in 2026: Verified US Provider List

There are four legitimate ways to get tirzepatide in 2026: Zepbound vials from LillyDirect ($299-$449/month), Zepbound pens at retail (list price up to about $1,086 per fill), Mounjaro off-label, or compounded tirzepatide via telehealth.

9 min read

Zepbound Maintenance Dose After Goal Weight: SURMOUNT-4 Evidence Review

There is no FDA-approved Zepbound taper after goal weight. SURMOUNT-4 showed roughly half of lost weight returns within 52 weeks of stopping; SURMOUNT-MAINTAIN found a 5 mg step-down keeps most of it. Obesity is a chronic disease, not a finite course.

11 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.2

HumeCare+

GLP-1 weight loss with real-time body-composition tracking to protect muscle

Read full review →

From $199/mo

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo (+ required membership)

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo (“starting at” price)

Get started →